stockrowNextCure, Inc.
NXTC Healthcare Biotechnology
- EPS
- +75.2%
- Free cash flow
- +57.2%
Quarter to June 2026, against a year earlier
Follow NXTC
Alert me
NextCure, Inc. (NXTC) EV/Sales
As of 6 November 2026, NextCure, Inc. (NXTC) trades at a EV/Sales of 0.4×. Over the past ten years it has ranged from −4.9× (December 2022) to 92.1× (January 2020); the current reading is higher than 83% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2020 | 0.7× | (99.23%) |
| FY2019 | 87.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Mar 2020 | 25.6× | (70.61%) |
| Dec 2019 | 87.0× | — |
| Sep 2019 | 0.0× | — |
| Jun 2019 | 0.0× | — |
| 1 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| RNAZ TransCode Therapeutics Inc. compare | n/m |
| AARD Aardvark Therapeutics, Inc. compare | n/m |
| FLNA Cassava Sciences, Inc. compare | n/m |
| NXTC NextCure, Inc. | 0.4× |
| CRVO CervoMed Inc. compare | 0.6× |
| EVAX Evaxion A/S - Sponsored ADR compare | 1.4× |
| CELU Celularity, Inc. compare | 3.4× |
| IGC IGC Pharma, Inc. compare | 19.3× |
| CVM Cel-Sci Corporation compare | 27.6× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)